期刊文献+

老年急性髓系白血病患者106例临床特点 被引量:2

下载PDF
导出
摘要 目的研究急性髓系白血病老年患者细胞遗传学及分子生物学特征。方法回顾性分析我中心初治老年急性髓系白血病患者106例,对其的染色体核型及基因突变进行研究。结果 106例患者中异常核型52例,检出率为49.06%。t(15;17)及t(8;21)预后良好核型的发生率分别为13.21%(14/106)与5.66%(6/106);预后不良的复杂核型及单体型核型的检出率分别为9.43%(10/106)及4.72%(5/106)。染色体预后分层:良好组、中危组、高危组所占比例分别为18.87%(20/106)、70.75%(75/106)与10.83%(11/106)。高危组预后较差。共21例患者行分子学检测,NPM1、FLT3-ITD及c-kit突变的发生率分别为23.81%、14.29%及4.76%,NPM1、FLT3-ITD突变者均为正常核型,c-kit突变只见于t(8;21)患者。结论老年患者预后良好核型低,预后不良核型则高。老年患者预后较差,高危组患者预后更差。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2013年第7期1551-1553,共3页 Chinese Journal of Gerontology
  • 相关文献

参考文献10

  • 1So CC,Wan TS,Chow JL,et al.A single-center cytogenetic study of 629 Chinese patients with de novo acute myeloid leukemia-evidence of major ethnic differences and a high prevalence of acute promyelocytic leukemia in Chinese patients(J).Cancer Genet,2011;204(8):430-8.
  • 2Cheng Y,Wang Y,Wang H,et al.Cytogenetic profile of de novo acute myeloid leukemia:a study based on 1432 patients in a single institution of China(J).Leukemia,2009;23(10):1801-6.
  • 3Shaffer LG,Tommemp N.ISCN(2005).An international system for hu-man cytogenetic nomenclature(M).Switzerland:Karger Baselpublicafion,2005:55-83.
  • 4Breems DA,van Putten WL,De Greef GE,et al.Monosomal karyotype in acute myeloid leukemia:a better indicator of poor prognosis than a com-plex karyotype(J).J Clin Oncol,2008;26(29):4791-7.
  • 5Rulina AV,Spirin PV,Prassolov VS.Activated leukemic oncogenes AML1-ETO and c-kit:role in development of acute myeloid leukemia and current approaches for their inhibition(J).Biochemistry(Mosc),2010;75(13):1650-66.
  • 6Medeiros BC,Othus M,Fang M,et al.Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia:the South-west Oncology Group(SWOG)experience(J).Blood,2010;116(13):2224-8.
  • 7刘辉,常乃柏,裴蕾,宁尚勇,李江涛,邢宝利,许小东.急性髓性白血病178例患者的细胞遗传学特征[J].中华内科杂志,2011,50(8):683-686. 被引量:7
  • 8Schneider F,Hoster E,Schneider S,et al.Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML(NK-AML)(J).Ann Hematol,2012;91(1):9-18.
  • 9Menzin J,Lang K,Earle CC,et al.The outcomes and costs of acute mye-loid leukemia among the elderly(J).Arch Inter Med,2002;162(14):1597-603.
  • 10Erba HP.Prognostic factors in elderly patients with AML and the impli-cations for treatment(J).Hematol Am Soc Hematol Educ Program,2007;2(1):420-8.

二级参考文献11

  • 1卢瑞南,李建勇.Fms样酪氨酸激酶3突变与恶性血液病[J].中华内科杂志,2005,44(2):157-158. 被引量:1
  • 2陈赛娟,曹琪,马志贵,苏欣莹,熊树民,叶菁,王振义,李秀松,沈志祥,张芬琴,孙关林,方智雯,欧阳仁荣,朱学宏,应大明,顾龙君,陈竺.急性非淋巴细胞白血病的细胞遗传学及其预后意义[J].中华血液学杂志,1996,17(2):61-63. 被引量:27
  • 3Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 2010, 116 : 354-365.
  • 4S|ovak ML, Kopecky KJ, Cassileth PA, et al. Karyotype analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 2000, 96: 4075- 4083.
  • 5Grimwade D, Walker H, Harrison G, et al. The predictive valueof hierachical cytogenetic classification in older adults with acute myeloid leukemia (AML) : analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood, 2001, 98: 1312-1320.
  • 6Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001 : 75-115.
  • 7Shaffer LG, Tommerup N. ISCN (2005). An International System for Human Cytogenetic Nomenclature. Switzerland: Karger Baselpublication, 2005 : 55-83.
  • 8Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol, 2008, 26: 4791-4797.
  • 9Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic eytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 1998, 92: 2322-2333.
  • 10Frhling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major detetTninants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood, 2006, 108: 3280-3288.

共引文献6

同被引文献24

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部